Connecticut's Recreational Marijuana Sales Overtake Medical Sales

Jun.16.2023
Connecticut's Recreational Marijuana Sales Overtake Medical Sales
Connecticut's recreational marijuana sales surpassed medical sales for the first time in May 2023.

Special statement:


This article is restricted to conducting industry and overseas market research and does not make any product recommendations or comment on any domestic policies.


The legality of the products reported in the article is only valid in overseas markets. Domestic readers are advised to take note and strictly abide by relevant laws and regulations in China.


This article does not constitute any investment or consumer advice.


The content of this article is not suitable for minors and they are prohibited from reading it.


According to a report by LAW360, data released by the Connecticut Department of Consumer Protection shows that since January 2023 when recreational marijuana sales were allowed in Connecticut, its revenue has exceeded that of medical marijuana for the first time in May.


According to the Connecticut Department of Consumer Protection, sales in the state's recreational marijuana market last month totaled $11.5 million, while sales of medical marijuana reached $11.2 million.


Image source: LAW360


In the same month, the quantity of products purchased by medical marijuana patients exceeded that of recreational marijuana consumers - the medical market sold 312,758 products, while the recreational market sold 292,054 products.


The organization stated that the average price for medical marijuana products in May was $35.86, while the average price for recreational marijuana products was $39.47.


Image source: LAW360


A spokesperson for the Connecticut Department of Consumer Protection explained that the term "product" refers to "items packaged and sold by the manufacturer, such as pre-rolled cigarettes, vases, food packaging, e-cigarettes, etc. The specific types of products vary based on the packaging methods used by the manufacturer.


The sale of recreational marijuana in Connecticut began in January of this year. The majority of retail marijuana sales outlets in the state also serve as distributors for medical marijuana, as newly licensed recreational marijuana stores are still in their early stages of development.


According to data from the Connecticut Consumer Protection Department, the total sales of medical and adult-use marijuana in Connecticut for the first five months of this year amounted to $98.2 million.


During this period, retail sales of products across various pharmacies amounted to approximately $43.4 million while medical marijuana sales amounted to approximately $54.7 million.


Connecticut's legislative body recently passed a bill (H.B. 6699) that includes various reforms to the state's retail marijuana market. These reforms now impose the same regulations and restrictions on the marijuana ingredient, THC, from enticing marijuana sources, as they do on adult-use marijuana products.


The legislative body also passed a separate bill (H.B. 6700) allowing licensed marijuana producers to convert their licenses to cultivate marijuana.


Reference:


In May, retail sales of marijuana in Connecticut surpassed the sales of medical marijuana.


This document has been generated through artificial intelligence translation and is provided solely for the purposes of industry discourse and learning. Please note that the intellectual property rights of the content belong to the original media source or author. Owing to certain limitations in the translation process, there may be discrepancies between the translated text and the original content. We recommend referring to the original source for complete accuracy. In case of any inaccuracies, we invite you to reach out to us with corrections. If you believe any content has infringed upon your rights, please contact us immediately for its removal.

BAT Shares Surge Nearly 6% as FDA Policy Shift Eases Pressure on Vuse and Velo
BAT Shares Surge Nearly 6% as FDA Policy Shift Eases Pressure on Vuse and Velo
British American Tobacco (BAT) shares rose sharply on May 12 after the U.S. Food and Drug Administration signaled it would deprioritize enforcement against certain unauthorized e-cigarette and nicotine pouch products with accepted premarket applications. Investors viewed the move as favoring established players such as BAT’s Vuse and Velo brands.
BAT
May.13
EU Launches Online Feedback as TPD Revision Enters New Milestone
EU Launches Online Feedback as TPD Revision Enters New Milestone
The European Commission has opened an online call for evidence on revising EU tobacco products and advertising rules, marking a new phase in the TPD/TAD review. Policy options may cover novel products, flavours, packaging, digital marketing and advertising. A 2Firsts review of 855 early submissions shows rapid engagement and recurring debate over differentiated regulation, harm reduction, youth protection, illicit trade and economic impact.
Special Report
May.21
JTI Invests EUR 300 Million in New Factory in Romania to Advance Its Localized Expansion
JTI Invests EUR 300 Million in New Factory in Romania to Advance Its Localized Expansion
After being present in Romania for more than 30 years, Japan Tobacco International (JTI) announced that it will invest approximately EUR 300 million (about USD 324 million) to build a green, state-of-the-art new factory in Ilfov County, Romania, reinforcing its long-term commitment to the country.
Mar.31 by 2FIRSTS.ai
Brazilian Research Institutions Prepare Joint Recommendations on Electronic Smoking Device Studies
Brazilian Research Institutions Prepare Joint Recommendations on Electronic Smoking Device Studies
Brazil’s National Cancer Institute, the Oswaldo Cruz Foundation, and other research institutions are preparing a joint letter with recommendations and guidance for studies on electronic smoking devices, including e-cigarettes, vapes, and similar products. The guidelines were discussed on April 14 and 15 at the seminar “Building a Priority Research Agenda on Electronic Smoking Devices for Brazil” in Rio de Janeiro.
Apr.16 by 2FIRSTS.ai
Nature Health Comment Urges Wider Role for Smoke-Free Nicotine Products in Tobacco Control
Nature Health Comment Urges Wider Role for Smoke-Free Nicotine Products in Tobacco Control
Ahead of World No Tobacco Day, a Nature Health Comment by Robert Beaglehole, Ruth Bonita and Tikki Pang argues that regulated smoke-free nicotine products could help accelerate the global decline in smoking. The authors propose a “smoke-free 2040” goal and call for risk-proportionate regulation distinguishing cigarettes from lower-risk nicotine alternatives.
News
May.20
FDA and IKE Tech Hold Formal Listening Session on Youth Access and Illicit ENDS Products
FDA and IKE Tech Hold Formal Listening Session on Youth Access and Illicit ENDS Products
U.S. Food and Drug Administration’s Center for Tobacco Products held a formal listening session with IKE Tech LLC to discuss youth prevention at the point of use for ENDS products, the circulation of illicit products in the supply chain, and the regulatory treatment of software in tobacco products.
Apr.10 by 2FIRSTS.ai